Folinic acid in colorectal cancer: esquire or fellow knight? Real-world results from a mono institutional, retrospective study
Francesco Jacopo Romano(Federico II University Hospital), Ferdinando Riccardi(Ospedale Antonio Cardarelli), Bruno Chiurazzi(Ospedale Antonio Cardarelli), Raffaella Ruocco(University of Naples Federico II), Carmen Mocerino(Ospedale Antonio Cardarelli), Carmela Barbato(Ospedale Antonio Cardarelli), Vincenzo Di Lauro(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Sarah Scagliarini(Ospedale Antonio Cardarelli), Maria Fiorella Brangi(Ospedale Antonio Cardarelli), Roberto Fiorentino(Ospedale Antonio Cardarelli), Dario Arundine(Ospedale Antonio Cardarelli), Livio Puglia(Ospedale Antonio Cardarelli), Maria Biglietto(Ospedale Antonio Cardarelli), Ivana Cerillo(University of Naples Federico II), Francesca Ambrosio(Azienda Ospedaliero-Universitaria Careggi), Maresa Cammarota(Ospedale Antonio Cardarelli)
Cited by 1
Related Papers
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
|Journal of Clinical Oncology|2012|234
Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
|International Journal of Molecular Sciences|2020|194
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial
|Journal of Clinical Oncology|2017|186
Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study
|The Journal of Clinical Endocrinology & Metabolism|2019|180
Real-World Study of Everolimus in Advanced Progressive Neuroendocrine Tumors
|The Oncologist|2014|103